Remove products how-drugs-are-made commitment-to-quality
article thumbnail

Innovations in Biosimilars: Insights and Trends from Samsung Bioepis

XTalks

Biosimilars offer a promising pathway to reducing healthcare costs while maintaining the efficacy and safety profiles of their reference products, the originally approved biologic drugs. Biosimilars have emerged as an important factor in modern healthcare, reshaping treatment accessibility and affordability.

article thumbnail

How to get acquisition ready – a seller’s guide to merger and acquisition in pharma

pharmaphorum

M&A is an integral part of the lifecycle of pharma companies and a key strategy to future-proof larger players, driving R&D activities and innovation for a competitive product pipeline. In addition to having attractive products, ensuring the supply chain of those products is secure is an increasing concern for companies.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The calm after the storm: How COVID-19 is making pharma more resilient

pharmaphorum

COVID-19 is proving to be the perfect storm in terms of the supply of pharmaceutical products. But learning how to overcome the challenges of 2020 will serve the industry well for years to come. First, we saw a doubling or tripling of usual demand for a lot of our products. Remote pharma.

article thumbnail

Investing in biologics excellence

pharmaphorum

In little over three decades, advances in biotechnology have noticeably disrupted the development landscape of small molecule drugs. Now, amid a wave of innovation, investors and drugmakers are putting their weight behind the drug class. Investing in biological production facilities. The rise of biologics.

article thumbnail

‘Voice of the Clinical Research Professional’ Heard in Comments Submitted to FDA on DCTs

ACRP blog

Food and Drug Administration (FDA) in response to the agency’s recent draft guidance on DCTs. Packaging and Shipping Considerations: Members highlighted challenges and considerations related to the packaging and shipping of investigational products in DCTs.

article thumbnail

‘Voice of the Clinical Research Professional’ Heard in Comments Submitted to FDA on DCTs

ACRP blog

Food and Drug Administration (FDA) in response to the agency’s recent draft guidance on DCTs. Packaging and Shipping Considerations: Members highlighted challenges and considerations related to the packaging and shipping of investigational products in DCTs.

article thumbnail

Touring Chiesi’s vision for the future at the new Biotech Centre of Excellence

pharmaphorum

Located on the outskirts of the historic Italian city – home to Verdi and myriad architectural gems – the press launch and tour of the €85 million Chiesi development was a quintessentially Italian affair, based out of Chiesi’s San Leonardo production site. In-house drug development of biologicals and rare disease targeting.